Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-iclaprim is the S-enantiomer of iclaprim, a synthetic small molecule antibiotic in the diaminopyrimidine class. It acts as a competitive inhibitor of bacterial dihydrofolate reductase (DHFR), disrupting folate synthesis and thereby inhibiting bacterial DNA replication and cell division. Like racemic iclaprim, it demonstrates potent activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae resistant to multiple antibiotics. Iclaprim has been investigated primarily for intravenous use in acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and skin structure infections (cSSSI). The S-enantiomer specifically refers to the stereochemistry at its chiral center[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-iclaprim.